Patent · US Active

Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced

US8563232B2 · kind B2 · utility

16Cited by
71References
41Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 28, 2003
Grant dateOct 22, 2013
Priority date
Expiry dateNov 25, 2028

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2509/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides methodologies and apparatus for producing devitalized soft-tissue implants where the implant retains metabolically non-viable and/or reproductively non-viable cells, and preferably retains large molecular weight cytoplasmic proteins, such implants produced both in small quantities and in commercializable quantities. Such soft-tissue implants include vascular graft substitutes. A devitalized graft is produced by subjecting the tissue sample to an induced pressure mediated flow of an extracting solution, optionally followed by inducing a pressure mediated flow of a salt solution, then washing the tissue to produce the devitalized graft. The devitalized grafts produced are uniform and non-immunogenic. The inventive method allows for the production of multiple devitalized soft tissue implants, where processing time is significantly less than prior art processes and the number of implants produced per day is increased over prior art processes. In clinical use, the devitalized grafts produced exhibit significantly improved in long-term durability and function, and enhanced recellularization post-implantation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.